Exelixis
EXEL
#1672
Rank
$13.40 B
Marketcap
$54.08
Share price
0.73%
Change (1 day)
39.71%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Annual Reports

Thumbnail Exelixis Annual Report 2025

Annual Report 2025

Language: English

View Annual Report
Thumbnail Exelixis Annual Report 2024

Annual Report 2024

Language: English

View Annual Report
Thumbnail Exelixis Annual Report 2023

Annual Report 2023

Language: English

View Annual Report
Thumbnail Exelixis Annual Report 2022

Annual Report 2022

Language: English

View Annual Report
Thumbnail Exelixis Annual Report 2021

Annual Report 2021

Language: English

View Annual Report
Thumbnail Exelixis Annual Report 2020

Annual Report 2020

Language: English

View Annual Report
Thumbnail Exelixis Annual Report 2019

Annual Report 2019

Language: English

View Annual Report
Thumbnail Exelixis Annual Report 2018

Annual Report 2018

Language: English

View Annual Report
Thumbnail Exelixis Annual Report 2017

Annual Report 2017

Language: English

View Annual Report
Thumbnail Exelixis Annual Report 2016

Annual Report 2016

Language: English

View Annual Report
Thumbnail Exelixis Annual Report 2015

Annual Report 2015

Language: English

View Annual Report